



Universiteit
Leiden
The Netherlands

Immune modulation by schistosomes: mechanisms of regulatory B cell induction and inhibition of allergic asthma

Obieglo, K.

Citation

Obieglo, K. (2019, February 28). *Immune modulation by schistosomes: mechanisms of regulatory B cell induction and inhibition of allergic asthma*. Retrieved from <https://hdl.handle.net/1887/69117>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/69117>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/69117> holds various files of this Leiden University dissertation.

Author: Obieglo, K.

Title: Immune modulation by schistosomes: mechanisms of regulatory B cell induction and inhibition of allergic asthma

Issue Date: 2019-02-28

Chapter

5

TYPE I INTERFERONS PROVIDE ADDITIVE SIGNALS FOR REGULATORY B CELL INDUCTION BY *S. MANSONI* *IN VITRO*, BUT DO NOT SYNERGIZE WITH *S.MANSONI*-SPECIFIC SIGNALS *IN VIVO*

Katja Obieglo, Alice Costain, Lauren M. Webb,
Arifa Ozir-Fazalalikhani, Shelia L. Brown,
Andrew S. MacDonald, and Hermelijn H. Smits

ABSTRACT

The helminth *Schistosoma mansoni* induces a network of regulatory immune cells, including interleukin (IL)-10-producing regulatory B (Breg) cells. However, the signals required for the development and activation of Breg cells are not well characterized. Recent reports suggest that helminths induce type I interferons (IFN-I), and that IFN-I drives the development of Breg cells in humans. We therefore assessed the role of IFN-I in the induction of Breg cells by *S. mansoni*. Chronic *S. mansoni* infection induced a systemic IFN-I signature. Recombinant IFN α enhanced IL-10 production by Breg cells stimulated with *S. mansoni* soluble egg antigen (SEA) *in vitro*, while not activating Breg cells by itself. IFN-I signalling also supported *ex vivo* IL-10 production by SEA-primed Breg cells, but was dispensable for activation of *S. mansoni* egg-induced Breg cells *in vivo*. These data show that while IFN-I can serve as a co-activator for Breg cell IL-10 production, they are not central *in vivo* in response to *S. mansoni*.

INTRODUCTION

The helminth *Schistosoma mansoni* induces a network of regulatory immune cells during the chronic phase of infection¹. The induction of B cells with regulatory properties, so called regulatory B (Breg) cells, by *S. mansoni* has been studied extensively²⁻⁵. Breg cells as part of the regulatory network play an important role in limiting immunopathology and attenuate responses to bystander antigens such as allergens⁶. Breg cell induction as observed during chronic infection can be replicated by soluble egg antigens (SEA)^{7,8} and even the single, egg-derived molecule IPSE/alpha-1⁸ in the absence of infection. While it is currently unclear which receptors and pathways *S. mansoni*-derived molecules engage, factors consistently reported to be important for Breg cell development and activation are stimulation through the B cell receptor (BCR⁹⁻¹²), CD40^{9, 13-16} and the toll-like receptors (TLR) TLR2/4¹⁷⁻¹⁹, TLR7²⁰ and TLR9¹⁷. Moreover, different cytokines including IL-21²¹, IL-35^{22, 23}, BAFF^{24, 25}, APRIL²⁶ and type I interferons (IFN-I)²⁷ have been described to support Breg cell development.

IFN-I are a large family of cytokines, containing 14 IFN α subtypes and a single IFN β , central in the immune response to viral infections²⁸. Induced, amongst others, by ligation of pattern recognition receptors (PRRs) of immune and non-immune cells, IFN-I act in an auto- and paracrine manner to induce an antiviral state, but can also interfere with innate and adaptive immune responses^{29, 30}. IFN-I can enhance antigen presentation and chemokine production in innate cells, promote effector T cell responses and induce B cell antibody production in viral infection (reviewed in³⁰). The role of IFN-I in bacterial, fungal and intracellular parasitic (mainly *Leishmania*, *Plasmodium* and *Trypanosoma* spp.) infections is complex, with possible beneficial and detrimental outcomes for the host (reviewed in²⁸). Only recently, reports have highlighted the potential of helminths or their products to induce IFN-I in mouse models. Infection with the gastrointestinal helminth *Heligmosomoides polygyrus* has been shown to induce IFN-I signalling in gut and lung in a microbiota-dependent manner, protecting mice from RSV infection³¹. *S. mansoni* eggs and SEA have been shown to induce an IFN-I signature both in splenic DCs and in *in vitro* differentiated bone marrow DCs (BMDCs)^{32, 33}, and *Nippostrongylus brasiliensis* induces IFN-I in skin DCs³⁴. A more generalized expression of IFN-stimulated genes (ISGs) in response to *S. mansoni* products has so far only been shown by Webb et al. for whole lung tissue following i.p. sensitization and i.v. challenge with *S. mansoni* eggs³³.

B cells express the IFN α/β receptor (IFNAR) and respond to IFN-I³⁵⁻³⁷. B cell responses to IFN-I are most extensively studied in autoimmunity. In systemic lupus erythematosus (SLE), IFN-I are considered to promote the activation of autoreactive B cells, maturation into plasmablasts and autoantibody production, contributing to disease pathology³⁸. Menon et al. add important knowledge to the picture by showing that plasmacytoid DCs (pDCs) drive the formation of IL-10-producing Breg cells by IFN α production and CD40 ligation in healthy individuals, but fail to do so in SLE patients. While Breg cell-derived IL-10 normally provides an important feedback loop that limits IFN α production, SLE patients have hyper-activated pDCs that fail to induce Breg cells, possibly due to Breg cells being less responsive to supra-optimal concentrations of IFN α ³⁹. In patients with certain types of multiple sclerosis (MS) IFN β therapy is a commonly applied treatment option. It has been reported that IFN β therapy not only increased IL-10 production by monocytes and T cells^{40, 41}, but also B cells and plasmablasts⁴².

Whereas Breg cells can be induced by *S. mansoni*-derived antigens *in vitro*, this is less potent than the induction of Breg cells during chronic infection, and the induction of Breg cells by IPSE/alpha-1 has only been demonstrated *in vitro*⁸. Helminth infections trigger a multitude of different immune responses in the host *in vivo*, and it is likely that additional signals, in addition to helminth molecules, are required for optimal Breg cell induction. Here, we sought to address whether IFN-I are central to the induction of Breg cells by *S. mansoni*. We show that *S. mansoni* infection induced a systemic IFN-I signature *in vivo*. Recombinant IFN α enhanced B cell IL-10 production in response to SEA and SEA+aCD40 *in vitro*, while blocking antibodies against IFNAR alpha chain (IFNAR1) reduced the *ex vivo*

IL-10 production by *in vivo*-primed B cells. However, B cell induction in response to egg administration *in vivo* was not affected in IFNAR^{-/-} mice. Collectively, these data show that IFN-I provide additive signals for Breg cell induction by *S. mansoni in vitro*, but are not crucial for *S. mansoni*-induced Breg cells *in vivo*.

RESULTS

S. mansoni* induces a systemic IFN-I signature *in vivo

We first sought to assess whether chronic *S. mansoni* infection induces a systemic IFN-I signature. High-dose infection with 180 *S. mansoni* cercariae significantly increased the serum concentration of IFN α 3 in the majority of animals (**Figure 1**), while lower doses of 20-40 cercariae did not (data not shown). Systemic levels of IL-5 and IL-12/23p40 were similarly increased, while IFN β , IL-10, and IL-17 were only elevated in a minority of animals (**Figure 1**). The production of IFN-I subtypes is often difficult to assess, as they are frequently produced at low levels and transiently, or consumed by neighbouring cells following production, which might explain the high dose of infection necessary to reliably detect IFN-I in the serum. Irrespective, the significant increase in serum IFN-I following high-dose infection supports the notion that *S. mansoni* induces a systemic IFN-I signature.

Recombinant IFN α enhances SEA/aCD40-induced B cell IL-10 production *in vitro*

We have previously demonstrated that SEA induces B cell IL-10 production and that CD40 ligation enhances SEA-induced Breg cell development⁸, while others have reported a synergistic effect of IFN α and CD40 ligation on the development of IL-10-producing human B cells³⁹. We therefore tested the effect of simultaneous stimulation of splenic B cells with SEA, agonistic anti-CD40 antibody (aCD40) and recombinant IFN α *in vitro*. After 3 days of culture, the concentration of IL-10 in culture supernatants of SEA-stimulated B cells increased with increasing doses of IFN α , whereas IFN α alone had no effect (**Figure 2A**). The strongest induction of B cell IL-10 production could be observed when cells were co-stimulated with SEA and aCD40, compared to SEA alone (**Figure 2A**). IFN α at concentrations of 10³-10⁴ U/mL (equivalent to circa 15-150ng/mL) significantly enhanced IL-10 production in response to SEA and SEA+aCD40, whereas IL-10 production seemed to plateau at 10⁵ U/mL IFN α (**Figure 2A**). IL-10 production after co-stimulation with IFN α increased up to 4-fold compared to the control condition without addition of IFN α . IFN α also enhanced IL-6 production, a pro-inflammatory cytokine known to be produced by B cells, in response to SEA and aCD40, albeit to a lesser extent (**Figure 2A**). This indicated a pattern of cytokine expression characteristic for Breg cells. Conversely, the percentage of IL-10-producing B cells after 3 days of stimulation with SEA or SEA+aCD40 in the presence of IFN α did not increase (**Figure 2B**). This suggests that the peak of the stimulatory activity of IFN α occurs earlier, possibly because of a decline in the IFN α concentration in culture supernatant due to consumption, and had already passed when the intracellular staining was performed after 3 days of culture. As a control, we also stimulated B cells with CpG ODN1826 (class B) and IFN α . Already a low concentration of 10³ U/mL IFN α strongly amplified the CpG ODN1826-induced cytokine production (**suppl. Figure 1A**) and the percentage of IL-10-producing B cells (**suppl. Figure 1B**). These data show that IFN α provides additional signals for the induction of B cell IL-10 production in cells activated with known Breg cell-inducing stimuli SEA or CpG ODN1826.

IFNAR1 signalling provides co-signals for IL-10 production by *in vivo* primed B cells

To assess whether IFN-I signalling provides important signals for IL-10 production by *in vivo* primed Breg cells, we treated mice with SEA i.p. and subsequently restimulated total splenocyte cultures ex

vivo with SEA in the presence or absence of blocking antibodies against IFNAR1. We also used blocking antibodies against CD40 ligand (CD40L) upon *ex vivo* restimulation to assess the importance of CD40 co-ligation on B cells for IL-10 induction. While blocking CD40L alone, or in combination with blocking IFNAR1, had either no or no additional effect, blocking IFNAR1 signalling significantly reduced the concentration of IL-10 in 2-day culture supernatants (**Figure 3A**). The production of IL-6 was not affected by either of the blocking agents (**Figure 3A**), while the percentage of IL-10 producing B cells in culture was mildly but significantly reduced by both blocking agents (**Figure 3B**). We concluded that signalling via IFNAR1, but not the ligation of CD40, is essential for SEA-induced B cell IL-10 production in this setting.




Figure 1. *S. mansoni* induces a systemic type I IFN signature. Mice were infected with 180 *S. mansoni* cercariae and serum samples taken at d49 of infection for assessment of cytokine levels by ELISA/CBA. Pooled data from 2 experiments, $n=20$ /group. Significant differences were determined by unpaired t-test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure 2. Recombinant IFN α enhances SEA/aCD40-induced B cell IL-10 production. B cells were isolated from the spleen of naïve mice and stimulated *in vitro* with SEA (20 μ g/mL), aCD40 (0.5 μ g/mL) and IFN α (10^3 - 10^5 U/mL) as indicated. After 3 days of culture, supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (**A**), and the percentage of IL-10 $^+$ B cells assessed by flow cytometry (**B**). Summary of 3 (**A**) or 2 (**B**) experiments, each data point is the mean of two technical replicates. Data are presented as mean $\pm$ SEM. Significant differences were determined by one-way ANOVA followed by Dunnett's multiple comparisons test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.




Figure 3. Ex vivo block of IFNAR1 reduces B cell IL-10 production. Splenocytes from SEA-injected mice (100 μ g SEA i.p. on d0 & d7; section d14) were re-stimulated ex vivo with SEA (20 μ g/mL) for 2 days in the presence or absence of anti-CD40L (aCD40L; 10 μ g/mL) and anti-IFNAR1 (aIFNAR1; 10 μ g/mL) blocking antibodies as indicated. After 2 days of culture, supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (**A**), and the percentage of IL-10⁺ B cells assessed by flow cytometry (**B**). Summary of 2 experiments, n=10/group. Data are presented as mean $\pm$ SEM. Significant differences were determined by RM-One Way ANOVA & Dunnett's post-test comparing all groups to the SEA-stimulated positive control. * p < 0.05, ** p < 0.01, *** p < 0.001.

IFNAR1 signalling is dispensable for Breg cell induction *in vivo*

To assess whether IFN-I signalling provides important signals for Breg cell development and IL-10 production in response to *S. mansoni* egg products not only *in vitro* but also *in vivo*, we induced Breg cell development by two doses of i.p. administered *S. mansoni* eggs (5000) in WT control or IFNAR1^{-/-} mice, a model we previously showed to be very suitable to demonstrate schistosome-induced splenic Breg cell development⁸. The absence of IFNAR1 did not affect the concentration of IL-10 in B cells and total splenocyte culture supernatants in response to restimulation with SEA and aCD40 (**Figure 4A**). In addition, the percentage of IL-10⁺ B cells seemed increased rather than decreased in IFNAR1^{-/-} mice (**Figure 4B**). Additionally, no changes in IL-10 production could be observed when blocking IFNAR1 signalling by means of *in vivo* administration of anti-mouse IFNAR1 blocking antibody (**suppl. Figure 2**). Thus IFNAR1 signalling seems to be dispensable for the induction of Breg cells to *S. mansoni* egg challenge *in vivo*.

DISCUSSION

In this study, we sought to address whether IFN-I might provide the 'missing link', synergizing with *S. mansoni*-derived signals for the induction of Breg cell IL-10 production. We show that, although *S. mansoni* infection induces a systemic IFN-I signature, and IFN-I signalling enhances *in vitro* IL-10 production by Breg cells exposed to *S. mansoni* antigens, IFN-I responsiveness is ultimately dispensable for Breg cell induction by *S. mansoni* eggs *in vivo*.

We and others have previously shown that chronic *S. mansoni* infection induces Breg cells^{3, 4, 43, 44}, and that this Breg cell-inducing effect can be replicated by isolated eggs, SEA and even the single, egg-derived molecule IPSE/ α -1 in the absence of adult worms and a natural infection^{7, 8}. Components of SEA directly bind to splenic B cells⁸, but the receptors ligated and signalling pathways activated by these antigens remain to be identified. Moreover, SEA immunization is less potent than chronic infection at Breg cell induction *in vivo*, and the induction of Breg cells by IPSE/ α -1 has only been demonstrated *in vitro*⁸. Helminth infections trigger a multitude of different immune responses in the host *in vivo*, and it is likely that additional signals, in addition to helminth molecules, are required for optimal Breg cell induction.

Our data showing an increased concentration of IFN-I in serum of mice actively infected with *S. mansoni* are in line with previous reports on the capacity of *S. mansoni* eggs or egg antigens,




Figure 4. IFNAR1 signalling is dispensable for Breg cell induction *in vivo*. Splenocytes and MACS-isolated CD19⁺ B cells from *S. mansoni* egg-injected mice (5000 *S. mansoni* eggs i.p. on d0 & d7; section d14) were re-stimulated *ex vivo* with SEA (20µg/mL) and aCD40 (2µg/mL) for 2 days. After 2 days of culture, supernatants of isolated B cell and total splenocyte cultures were analyzed for IL-10 concentration by ELISA (**A**), and the percentage of IL-10⁺ B cells within splenocyte cultures assessed by flow cytometry (**B**). Summary of 2 experiments, n=8-10/group. Data are presented as mean ± SEM. Significant differences were determined by one-way ANOVA followed by Tukey's multiple comparisons test. ** p < 0.01, *** p < 0.001.

H. polygus infection and *N. brasiliensis* antigens to induce IFN-I³¹⁻³⁴. pDCs are considered an important source of IFN-I⁴⁵. IFN-I were however produced by conventional DCs (cDCs) rather than pDCs after SEA-stimulation of BMDCs *in vitro*³³. We have not addressed the cellular source of IFN-I in our study, therefore both pDCs and cDCs remain possible sources. Notably, little is reported to date regarding IFN-I production by human DCs in response to helminths, but work of our own group suggests that *S. mansoni* egg antigens do not induce IFN-I in human monocyte-derived DCs (Everts, personal communication).

We here show that recombinant IFNα, while having no measurable effect on its own, significantly and dose-dependently increased IL-10 production by B cells in response to *in vitro* stimulation with SEA alone or SEA+aCD40. IFNα also had a synergistic effect on SEA+aCD40-induced IL-6 production, albeit to lesser extent. Conversely, the percentage of IL-10⁺ B cells was unchanged or slightly reduced after 3 days of culture in the presence of increasing amounts of IFNα, suggesting that IFN-I may change the dynamics and timing of IL-10 production. Menon et al. observed an optimal IL-10 induction in naïve TLR9-stimulated B cells at 50x10⁵ U/mL IFNα and a less effective stimulation at higher concentrations³⁹, whereas we find an additive effect even at 1x10⁶ U/mL on both SEA- and TLR9-stimulated B cells on IL-10 concentration in culture supernatants. The fact that IFNα has no effect at all on IL-10 or IL-6 expression by itself underpins that IFN-I signalling modulates responses in pre-activated B cells rather than providing an activation signal to B cells by itself, which has been similarly reported by others^{27, 42}. In this context, it is plausible that stimulation with *S. mansoni*-derived antigens *in vitro* provides this pre-activation signal, rather than SEA- and IFN-I-specific signalling pathways synergizing to promote B cell IL-10 production. This is in line with previous reports describing IFN-I signalling to regulate B cell responses to other pre-activating stimuli such as BCR or TLR7 ligation^{35, 36}. In this context, Braun et al. show that murine, mature splenic B cells get partially activated by treatment with IFNα/β, characterized by the upregulation of activation markers and increased survival in the absence of proliferation or terminal differentiation, and display enhanced response to BCR ligation³⁵. Poovassery and colleagues report that both BCR and IFNAR signalling restore TLR7-induced B cell hyporesponsiveness³⁶. That the percentage IL-10⁺ B cells tends to decrease at the end of culture might suggest that the peak of IFNα stimulatory activity has occurred earlier and that after 3

days of culture the IFN-I concentration in culture supernatant has already declined, making an earlier time point for the assessment of IL-10⁺ B cells preferable.

Arguably, *in vitro* stimulation of isolated B cells with recombinant IFN α does not mimic the natural situation very well. We therefore also assessed the role of IFN-I signalling on Breg cell recall responses *ex vivo*. Blocking IFNAR1 upon *ex vivo* restimulation of *in vivo* SEA-induced Breg cells significantly reduced IL-10, but not IL-6 production. Adding blocking antibodies against CD40L to the cultures, and thereby preventing the ligation of CD40 expressed on B cells by accessory cells present in whole splenocyte cultures, had only negligible effects. This might indicate that, while CD40 ligation has previously been shown to enhance B cell IL-10 expression^{8,9,15}, it does not provide additional signals for B cell IL-10 production in this restimulation setting. This might point at a difference in the contribution of CD40 signalling to Breg cell induction upon concurrent priming of B cells with an antigen and agonistic aCD40⁸ and upon *ex vivo* restimulation as performed in this study. Finally, we found B cell IL-10 production to be unaltered in IFNAR1^{-/-} mice upon egg i.p. administration, suggesting that IFN-I signalling is dispensable in this setting. This strongly suggests that *in vivo*, where multiple pathways are activated simultaneously and potentially act synergistically, IFN-I signalling does not play a major additive role for the development and activation of Breg cells in response to *S. mansoni*.

The physiological role of IFN-I in helminth infections has not been extensively studied to date. Enteric *H. polygyrus*-induced IFN-I protects from RSV co-infection³¹. SEA-stimulated BMDCs induce IFN-I³², and SEA-stimulated cDCs as well as skin DCs exposed to *N. brasiliensis* were shown to be dependent on IFN-I signalling for their effective induction of Th2 response^{33,34}. Therefore, more research is needed to fully understand the role of IFN-I in helminth and, more specifically, in *S. mansoni* infections.

Collectively, the data presented here show that, while IFN-I can enhance IL-10 production by *S. mansoni*-activated Breg cells both *in vitro* and *ex vivo*, IFN-I signalling is dispensable for the formation and activation of *S. mansoni*-induced Breg cells *in vivo*. A better understanding of the signals for optimal Breg cell development and activation is required to develop novel therapies around Breg cells.

MATERIAL AND METHODS

Animals

Female C57BL/6 mice (Harlan) were housed under SPF conditions in the animal facility of the Leiden University Medical Center (Leiden, The Netherlands). *Ifnar1*^{-/-} mice on an C56BL/6 background were housed at the University of Manchester. All animals were used for experiments at 6-12 weeks of age. All animal studies were performed in accordance with either the Animal Experiments Ethical Committee of the Leiden University Medical Centre or under a license granted by the home office (UK) in accordance with local guidelines.

S. mansoni infection & preparation of SEA

Routinely, mice were infected percutaneously with approximately 40 cercariae, and all readouts were performed during the chronic phase of infection (14-16 weeks p.i.). For the high dose infection model, mice were infected with approximately 180 cercariae and serum collected on day 49 after infection. *S. mansoni* eggs were isolated from trypsinized livers or guts of hamsters after 50 days of infection, washed in RPMI medium supplemented with penicillin (300U/mL), streptomycin (300 μ g/mL) and amphotericin B (300 μ g/mL) and stored at -80°C until use. SEA was prepared as previously described⁴⁶. Protein concentration was determined by BCA. SEA preparations were routinely tested for endotoxin contamination by Limulus Amoebocyte Lysate (LAL) assay or TLR4-transfected HEK reporter cell lines.

Splenocyte and B cell isolation

Spleens were homogenized by passage through a 70µm cell strainer (BD Biosciences) and erythrocytes depleted from the single cell suspension by lysis. B cells were purified from splenocytes by anti-CD19 MicroBeads (Miltenyi Biotec) following the manufacturer's instructions.

In vitro stimulation

Splenic CD19⁺ B cells (1.5x10⁶/mL) were cultured in medium (RPMI 1640 GlutaMAX; Thermo Fisher Scientific) supplemented with 5% heat-inactivated fetal calf serum (FCS; Greiner Bio-One) 2-mercaptoethanol (5x10⁻⁵ M), penicillin (100U/mL) and streptomycin (100µg/mL; all Sigma-Aldrich). Cells were stimulated with the following stimuli as indicated in the figures: SEA (20µg/mL), aCD40 (clone 1C10; 0.5µg/mL; Biolegend), recombinant IFNα (Biolegend), CpG ODN 1826 (class B; 0.2-1µM; Invivogen), aCD40L blocking antibody (clone MR1; 10µg/mL; kind gift from L. Boon, Bioceros), aIFNAR1 blocking antibody (clone MAR1-5A3; 10µg/mL; eBioscience).

Flow cytometry

Cells were stained with antibodies against B220 (clone RA3-6B2), CD21 (clone 7G6), CD23 (clone B3B4) and IL-10 (clone JESS-16E3). Dead cells were stained with live/dead fixable aqua dead cell stain kit (ThermoScientific). FcγR-binding inhibitor (2.4G2, kind gift of L. Boon, Bioceros) was added to all stainings. Flow cytometry was performed on a FACS Canto II using FACSDiva software (BD Biosciences) followed by data analysis using FlowJo.

ELISA and CBA

The concentration of IL-6 and IL-10 in cell-free culture supernatants was assessed by OptEIA ELISA kits (BD Biosciences) according to the manufacturer's instructions. The concentration of cytokines in serum of chronically infected mice was assessed by BD cytometric bead array (CBA) Flex-set kits (BD Biosciences), except for IFNα3 and IFNβ which were measured by ELISA (PBL).

Statistical analysis

Statistical analysis was performed using GraphPad Prism (version 7.02). All data are presented as mean ± standard error of the mean (SEM). P-values < 0.05 were considered statistically significant.

ACKNOWLEDGEMENTS

The work was supported by a ZonMW-VIDI grant (91714352) from Nederlandse Organisatie voor Wetenschappelijk Onderzoek appointed to HHS. The authors declare no conflict of interest.

REFERENCES

1. McSorley HJ, Maizels RM. Helminth infections and host immune regulation. *Clin Microbiol Rev.* 2012;25(4):585-608.
2. Jankovic D, Cheever AW, Kullberg MC, Wynn TA, Yap G, Caspar P, et al. CD4⁺ T cell-mediated granulomatous pathology in schistosomiasis is downregulated by a B cell-dependent mechanism requiring Fc receptor signaling. *J Exp Med.* 1998;187(4):619-29.
3. Amu S, Saunders SP, Kronenberg M, Mangan NE, Atzberger A, Fallon PG. Regulatory B cells prevent and reverse allergic airway inflammation via FoxP3-positive T regulatory cells in a murine model. *J Allergy Clin Immunol.* 2010;125(5):1114-24 e8.
4. van der Vlugt LE, Labuda LA, Ozir-Fazalalikhani A, Lievers E, Gloudemans AK, Liu KY, et al. Schistosomes induce regulatory features in

- human and mouse CD1d(hi) B cells: inhibition of allergic inflammation by IL-10 and regulatory T cells. *PLoS One*. 2012;7(2):e30883.
5. Finlay CM, Walsh KP, Mills KH. Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases. *Immunol Rev*. 2014;259(1):206-30.
6. Maizels RM, Yazdanbakhsh M. Immune regulation by helminth parasites: cellular and molecular mechanisms. *Nat Rev Immunol*. 2003;3(9):733-44.
7. Tian F, Hu X, Xian K, Zong D, Liu H, Wei H, et al. B10 cells induced by *Schistosoma japonicum* soluble egg antigens modulated regulatory T cells and cytokine production of T cells. *Parasitol Res*. 2015;114(10):3827-34.
8. Haeberlein S, Obieglo K, Ozir-Fazalikhani A, Chaye MAM, Veninga H, van der Vlugt L, et al. Schistosome egg antigens, including the glycoprotein IPSE/alpha-1, trigger the development of regulatory B cells. *PLoS Pathog*. 2017;13(7):e1006539.
9. Fillatreau S, Sweeney CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. *Nat Immunol*. 2002;3(10):944-50.
10. Miles K, Heaney J, Sibinska Z, Salter D, Savill J, Gray D, et al. A tolerogenic role for Toll-like receptor 9 is revealed by B-cell interaction with DNA complexes expressed on apoptotic cells. *Proc Natl Acad Sci U S A*. 2012;109(3):887-92.
11. Yanaba K, Bouaziz JD, Matsushita T, Tsubata T, Tedder TF. The development and function of regulatory B cells expressing IL-10 (B10 cells) requires antigen receptor diversity and TLR signals. *J Immunol*. 2009;182(12):7459-72.
12. Matsumoto M, Fujii Y, Baba A, Hikida M, Kurosaki T, Baba Y. The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production. *Immunity*. 2011;34(5):703-14.
13. Mizoguchi E, Mizoguchi A, Preffer FI, Bhan AK. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. *Int Immunol*. 2000;12(5):597-605.
14. Evans JG, Chavez-Rueda KA, Eddaoudi A, Meyer-Bahlburg A, Rawlings DJ, Ehrenstein MR, et al. Novel suppressive function of transitional 2 B cells in experimental arthritis. *J Immunol*. 2007;178(12):7868-78.
15. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of arthritis by interleukin 10-producing B cells. *J Exp Med*. 2003;197(4):489-501.
16. Mauri C, Mars LT, Londei M. Therapeutic activity of agonistic monoclonal antibodies against CD40 in a chronic autoimmune inflammatory process. *Nat Med*. 2000;6(6):673-9.
17. Lampropoulou V, Hoehlig K, Roch T, Neves P, Calderon Gomez E, Sweeney CH, et al. TLR-activated B cells suppress T cell-mediated autoimmunity. *J Immunol*. 2008;180(7):4763-73.
18. Wang K, Tao L, Su J, Zhang Y, Zou B, Wang Y, et al. TLR4 supports the expansion of FasL(+)CD5(+) CD1d(hi) regulatory B cells, which decreases in contact hypersensitivity. *Mol Immunol*. 2017;87:188-99.
19. Buenafe AC, Bourdette DN. Lipopolysaccharide pretreatment modulates the disease course in experimental autoimmune encephalomyelitis. *J Neuroimmunol*. 2007;182(1-2):32-40.
20. Khan AR, Amu S, Saunders SP, Hams E, Blackshields G, Leonard MO, et al. Ligation of TLR7 on CD19(+) CD1d(hi) B cells suppresses allergic lung inflammation via regulatory T cells. *Eur J Immunol*. 2015;45(6):1842-54.
21. Yoshizaki A, Miyagaki T, DiLillo DJ, Matsushita T, Horikawa M, Kountikov EI, et al. Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. *Nature*. 2012;491(7423):264-8.
22. Wang RX, Yu CR, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev YV, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. *Nat Med*. 2014;20(6):633-41.
23. Shen H, Wang C, Fan E, Li Y, Zhang W, Zhang L. Upregulation of interleukin-35 subunits in regulatory T cells in a murine model of allergic rhinitis. *ORL J Otorhinolaryngol Relat Spec*. 2014;76(5):237-47.
24. Walters S, Webster KE, Sutherland A, Gardam S, Groom J, Liuwantara D, et al. Increased CD4+Foxp3+ T cells in BAFF-transgenic mice suppress T cell effector responses. *J Immunol*. 2009;182(2):793-801.
25. Yang M, Sun L, Wang S, Ko KH, Xu H, Zheng BJ, et al. Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. *J Immunol*. 2010;184(7):3321-5.
26. Hua C, Audo R, Yeremenko N, Baeten D, Hahne M, Combe B, et al. A proliferation inducing ligand (APRIL)

- promotes IL-10 production and regulatory functions of human B cells. *J Autoimmun.* 2016;73:64-72.
27. Matsumoto M, Baba A, Yokota T, Nishikawa H, Ohkawa Y, Kayama H, et al. Interleukin-10-producing plasmablasts exert regulatory function in autoimmune inflammation. *Immunity.* 2014;41(6):1040-51.
 28. McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A. Type I interferons in infectious disease. *Nat Rev Immunol.* 2015;15(2):87-103.
 29. Gonzalez-Navajas JM, Lee J, David M, Raz E. Immunomodulatory functions of type I interferons. *Nat Rev Immunol.* 2012;12(2):125-35.
 30. Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. *Nat Rev Immunol.* 2014;14(1):36-49.
 31. McFarlane AJ, McSorley HJ, Davidson DJ, Fitch PM, Errington C, Mackenzie KJ, et al. Enteric helminth-induced type I interferon signaling protects against pulmonary virus infection through interaction with the microbiota. *J Allergy Clin Immunol.* 2017;140(4):1068-78 e6.
 32. Trottein F, Pavelka N, Vizzardelli C, Angeli V, Zouain CS, Pelizzola M, et al. A type I IFN-dependent pathway induced by *Schistosoma mansoni* eggs in mouse myeloid dendritic cells generates an inflammatory signature. *J Immunol.* 2004;172(5):3011-7.
 33. Webb LM, Lundie RJ, Borger JG, Brown SL, Connor LM, Cartwright AN, et al. Type I interferon is required for T helper (Th) 2 induction by dendritic cells. *EMBO J.* 2017;36(16):2404-18.
 34. Connor LM, Tang SC, Cognard E, Ochiai S, Hilligan KL, Old SI, et al. Th2 responses are primed by skin dendritic cells with distinct transcriptional profiles. *J Exp Med.* 2017;214(1):125-42.
 35. Braun D, Caramalho I, Demengeot J. IFN- α /beta enhances BCR-dependent B cell responses. *Int Immunol.* 2002;14(4):411-9.
 36. Poovassery JS, Bishop GA. Type I IFN receptor and the B cell antigen receptor regulate TLR7 responses via distinct molecular mechanisms. *J Immunol.* 2012;189(4):1757-64.
 37. Kiefer K, Oropallo MA, Cancro MP, Marshak-Rothstein A. Role of type I interferons in the activation of autoreactive B cells. *Immunol Cell Biol.* 2012;90(5):498-504.
 38. Crow MK. Type I interferon in the pathogenesis of lupus. *J Immunol.* 2014;192(12):5459-68.
 39. Menon M, Blair PA, Isenberg DA, Mauri C. A Regulatory Feedback between Plasmacytoid Dendritic Cells and Regulatory B Cells Is Aberrant in Systemic Lupus Erythematosus. *Immunity.* 2016;44(3):683-97.
 40. Kozovska ME, Hong J, Zang YC, Li S, Rivera VM, Killian JM, et al. Interferon beta induces T-helper 2 immune deviation in MS. *Neurology.* 1999;53(8):1692-7.
 41. Liu H, MacKenzie-Graham AJ, Kim S, Voskuhl RR. Mice resistant to experimental autoimmune encephalomyelitis have increased thymic expression of myelin basic protein and increased MBP specific T cell tolerance. *J Neuroimmunol.* 2001;115(1-2):118-26.
 42. Schubert RD, Hu Y, Kumar G, Szeto S, Abraham P, Winderl J, et al. IFN- β treatment requires B cells for efficacy in neuroautoimmunity. *J Immunol.* 2015;194(5):2110-6.
 43. Mangan NE, van Rooijen N, McKenzie AN, Fallon PG. Helminth-modified pulmonary immune response protects mice from allergen-induced airway hyperresponsiveness. *J Immunol.* 2006;176(1):138-47.
 44. Smits HH, Hammad H, van Nimwegen M, Soullie T, Willart MA, Lievers E, et al. Protective effect of *Schistosoma mansoni* infection on allergic airway inflammation depends on the intensity and chronicity of infection. *J Allergy Clin Immunol.* 2007;120(4):932-40.
 45. Fitzgerald-Bocarsly P, Dai J, Singh S. Plasmacytoid dendritic cells and type I IFN: 50 years of convergent history. *Cytokine Growth Factor Rev.* 2008;19(1):3-19.
 46. Everts B, Perona-Wright G, Smits HH, Hokke CH, van der Ham AJ, Fitzsimmons CM, et al. Omega-1, a glycoprotein secreted by *Schistosoma mansoni* eggs, drives Th2 responses. *J Exp Med.* 2009;206(8):1673-80.

SUPPLEMENTARY MATERIAL




Figure S1. Recombinant IFN α enhances CpG-induced B cell IL-10 and IL-6 production. B cells were isolated from the spleen of naïve mice and stimulated *in vitro* with CpG ODN1826 (class B; 0.2-1 μ M) and IFN α (10³-10⁴ U/mL) as indicated. After 3 days of culture, supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (A), and % IL-10 B cells assessed by flow cytometry (B). Summary of 2-3 experiments, each data point is the mean of two technical replicates. Data are presented as mean $\pm$ SEM. Significant differences were determined by one-way ANOVA followed by Dunnett's multiple comparisons test. * $p < 0.05$, *** $p < 0.001$.




Figure S2. IFNAR1 signaling is dispensable for Breg cell induction *in vivo*. Mice were treated as depicted in A. On day 14, spleens were harvested and total splenocyte cell suspensions and isolated CD19⁺ B cells restimulated with SEA (20ug/ml) and aCD40 (2ug/ml) for 2 days. Supernatants were analyzed for IL-10 and IL-6 concentration by ELISA (B), and the percentage of IL-10⁺ B cells assessed by flow cytometry (C). Data from one experiment, n=5/group. Data are presented as mean $\pm$ SEM. Significant differences were determined by one-way ANOVA followed by Tukey's multiple comparisons test. * $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$.